An International Phase Ib multicentre study to characterize the safety and tolerability of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with orally administered venetoclax, a selective Bcl-2 inhibitor, in patients with Acute Myeloid Leukaemia (AML).